Futibatinib had accelerated FDA approval on 30 September 2022 for previously treated adult patients with unresectable, locally advanced, or metastatic intrahepatic CCA with FGFR2 fusions or rearrangements. Here, FGFR2 is linked to cholangiocarcinoma.